In addition, metabolomic analysis of the gut microbiota in 11 patients with non-small cell lung cancer (NSCLC) receiving anti-PD-1 antibody therapy revealed that elevated levels of SCFAs, lysine, and niacin were significantly associated with long-term clinical benefit. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.